Olaratumab
- Product Name
- Olaratumab
- CAS No.
- 1024603-93-7
- Chemical Name
- Olaratumab
- Synonyms
- IMC3G3;IMC 3G3;IMC-3G3;Lartruvo;LY3012207;LY-3012207;LY 3012207;Olaratumab;LY3012207|||IMC-3G3;Olaratumab (anti-PDGFRA)
- CBNumber
- CB84845999
- Formula Weight
- 0
- MOL File
- Mol file
Olaratumab Property
- form
- Liquid
- color
- Colorless to light yellow
Olaratumab Chemical Properties,Usage,Production
Uses
Olaratumab (IMC-3G3; LY3012207) is an anti-platelet-derived growth factor receptor alpha (PDGFRα) human monoclonal IgG1 antibody with antitumor activity[1].
Clinical Use
Monoclonal antibody:
Treatment of advanced soft tissue sarcoma in
combination with doxorubicin
in vivo
IMC-3G3 (i.p., 40 mg/kg, three times per week, 6 weeks) in SKOV3-ip1 tumor-bearing mice, compared with the control group, IMC-3G3 treatment alone had no obvious anti-tumor effect, while in HeyA8 tumor-bearing mice, IMC-3G3 monotherapy showed a significant anti-tumor effect compared with the control group, with a tumor reduction rate of 62%[1].
Drug interactions
Potentially hazardous interactions with other drugs
Live vaccines: avoid with olaratumab in combination
with doxorubicin.
Metabolism
Mainly degraded non-specifically by proteolytic enzymes.
References
[1] Koji Matsuo, et al. Platelet-derived growth factor receptor alpha (PDGFRα) targeting and relevant biomarkers in ovarian carcinoma. Gynecol Oncol. 2014 Jan;132(1):166-75. DOI:10.1016/j.ygyno.2013.10.027